BioCentury
ARTICLE | Company News

AbbVie, Turnstone in oncolytic virus deal

October 10, 2017 10:18 PM UTC

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad-MG1-MAGEA3.

By combining oncolytic viruses with cancer vaccines, Turnstone aims to develop products with efficacy advantages over each individual modality (see BioCentury, Feb. 22, 2016)...